ATE381346T1 - Assayverfahren für alzheimer-krankheit - Google Patents

Assayverfahren für alzheimer-krankheit

Info

Publication number
ATE381346T1
ATE381346T1 AT02766022T AT02766022T ATE381346T1 AT E381346 T1 ATE381346 T1 AT E381346T1 AT 02766022 T AT02766022 T AT 02766022T AT 02766022 T AT02766022 T AT 02766022T AT E381346 T1 ATE381346 T1 AT E381346T1
Authority
AT
Austria
Prior art keywords
disease
alzheimer
beta
assay procedure
preclinical
Prior art date
Application number
AT02766022T
Other languages
German (de)
English (en)
Inventor
David Holtzman
Ronald Demattos
Kelly Bales
David Cummins
Steven Paul
Audrey Yunhua Jia
Naoya Tsurushita
Maximiliano J Vasques
Original Assignee
Univ Washington
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington, Lilly Co Eli filed Critical Univ Washington
Application granted granted Critical
Publication of ATE381346T1 publication Critical patent/ATE381346T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT02766022T 2001-08-17 2002-08-16 Assayverfahren für alzheimer-krankheit ATE381346T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31322401P 2001-08-17 2001-08-17
US31322101P 2001-08-17 2001-08-17
US33498701P 2001-10-23 2001-10-23

Publications (1)

Publication Number Publication Date
ATE381346T1 true ATE381346T1 (de) 2008-01-15

Family

ID=27405654

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02766022T ATE381346T1 (de) 2001-08-17 2002-08-16 Assayverfahren für alzheimer-krankheit

Country Status (10)

Country Link
EP (1) EP1416965B8 (enExample)
JP (2) JP4511830B2 (enExample)
AT (1) ATE381346T1 (enExample)
CA (1) CA2457145C (enExample)
CY (1) CY1107901T1 (enExample)
DE (1) DE60224200T2 (enExample)
DK (1) DK1416965T3 (enExample)
ES (1) ES2295401T3 (enExample)
PT (1) PT1416965E (enExample)
WO (1) WO2003015617A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA006606B1 (ru) 2000-02-24 2006-02-24 Вашингтон Юниверсити Гуманизированное антитело и его фрагмент, взаимодействующие с бета-амилоидным пептидом, и способы их применения
EP1944040B1 (en) 2001-08-17 2012-08-01 Washington University Assay method for Alzheimer's disease
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
ES2344645T3 (es) 2003-02-10 2010-09-02 Applied Molecular Evolution, Inc. Moleculas de union al abeta.
EP1480041A1 (en) * 2003-05-22 2004-11-24 Innogenetics N.V. Method for the prediction, diagnosis and differential diagnosis of Alzheimer's disease
GB0519398D0 (en) * 2005-09-23 2005-11-02 Antisoma Plc Biological materials and uses thereof
PL1976877T5 (pl) 2005-11-30 2017-09-29 Abbvie Inc Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania
RU2442793C2 (ru) 2005-11-30 2012-02-20 Эбботт Лэборетриз АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008088983A1 (en) 2007-01-18 2008-07-24 Eli Lilly And Company PEGYLATED Aβ FAB
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
JP5704533B2 (ja) * 2009-02-13 2015-04-22 国立大学法人大阪大学 アルツハイマー病の診断方法および診断薬
EP2510359B1 (en) 2009-12-11 2015-09-02 Araclón Biotech, S. L. Methods and reagents for improved detection of amyloid beta peptides
WO2011130377A2 (en) 2010-04-15 2011-10-20 Abbott Laboratories Amyloid-beta binding proteins
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
EP2511296A1 (en) 2011-04-12 2012-10-17 Araclón Biotech, S. L. Antibody, kit and method for determination of amyloid peptides
ES2874704T3 (es) * 2013-11-20 2021-11-05 Univ Iowa Res Found Procedimiento para monitorizar la eficacia de un tratamiento de la enfermedad de Alzheimer con una isoforma de ApoE
CN109187981A (zh) * 2018-08-01 2019-01-11 万东山 一种快速检测β-淀粉样蛋白的量子点免疫层析试纸条与应用
KR102496845B1 (ko) * 2018-08-08 2023-02-08 서울대학교산학협력단 진단 지표로서 베타-아밀로이드 수준과 함께 혈장 타우 수준을 사용하는 알츠하이머병의 진단 및 치료 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994010569A1 (en) * 1992-10-26 1994-05-11 Schenk Dale B METHODS AND COMPOSITIONS FOR THE DETECTION OF SOLUBLE β-AMYLOID PEPTIDE
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6730778B2 (en) * 1997-12-19 2004-05-04 Pharmacia And Upjohn Company Human sel-10 polypeptides and polynucleotides that encode them
EA006606B1 (ru) * 2000-02-24 2006-02-24 Вашингтон Юниверсити Гуманизированное антитело и его фрагмент, взаимодействующие с бета-амилоидным пептидом, и способы их применения

Also Published As

Publication number Publication date
PT1416965E (pt) 2008-04-01
EP1416965B8 (en) 2008-02-13
WO2003015617A3 (en) 2004-01-29
DK1416965T3 (da) 2008-05-05
CY1107901T1 (el) 2013-09-04
DE60224200T2 (de) 2008-07-10
JP2004538477A (ja) 2004-12-24
EP1416965A2 (en) 2004-05-12
CA2457145C (en) 2010-12-21
ES2295401T3 (es) 2008-04-16
JP5162553B2 (ja) 2013-03-13
EP1416965B1 (en) 2007-12-19
HK1061960A1 (en) 2004-10-15
WO2003015617A2 (en) 2003-02-27
JP4511830B2 (ja) 2010-07-28
DE60224200D1 (de) 2008-01-31
CA2457145A1 (en) 2003-02-27
JP2010044078A (ja) 2010-02-25
EP1416965A4 (en) 2005-11-02

Similar Documents

Publication Publication Date Title
CY1107901T1 (el) Μεθοδος προσδιορισμου για ασθενεια alzheimer
EP1944040A3 (en) Assay method for Alzheimer's disease
EA200700083A1 (ru) Антитела, направленные против бета-амилоидного пептида, и способы их применения
AU2002237296A1 (en) Conformationally abnormal forms of tau proteins and specific antibodies thereto
FR19C1028I2 (fr) Anticorps greffes avec cdr humains et fragments de ces anticorps
WO2002067760A3 (en) Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
BRPI0413556A (pt) sondas para doenças onde amilóide se acumula, agentes para tingimento de amilóide, drogas para tratamento e profilaxia de doenças com amilóide acumulada e sondas para diagnóstico de emaranhados neurofibrilares e agentes para tingimento de emaranhados neurofibrilares
ES2138729T3 (es) Metodos de diagnostico de la preeclampsia.
DE69333076D1 (de) Test und behandlung von demyelinierenden krankheiten wie multiple sklerosis
ATE234466T1 (de) Verfahren zur feststellung von antipolymerantikörper und diagnosetestsatz zur feststellung von siliconabhängigen krankheiten
ATE159300T1 (de) Monoklonale antikörper gegen menschliches ige
ATE318328T1 (de) Diagnostika und therapeutika für osteoporose
EP1017845A4 (en) Diagnostic test for alzheimer's disease
BRPI0407213A (pt) Método de emprego da elevação de marinobufagenina na determinação da presença de pré-eclampsia e aparelhos relacionados
DE602006019582D1 (de) Adarb2 proteine als diagnostische und therapeutische targets für neurodegenerative erkrankungen
WO2002074322A3 (en) Human growth hormone for treating children with abnormal short stature and kits and methods for diagnosing gs protein dysfunctions
DE50214523D1 (de) Nukleotidträger zur diagnose und therapie oraler erkrankungen
WO2000071081A3 (en) Methods of diagnosis and treatment of meniere disease
MX9704717A (es) Antigeno, anticuerpos y ensayo de diagnostico para la enfermedad de alzheimer.
ATE441859T1 (de) Verfahren zur diagnose der immunität wiederkehrenden spontanen schwangerschaftsabbruchs sowie verfahren zur behandlung und überwachung
WO2002088345A3 (en) Murine dnasex, medicament containing the same and non-human mammal comprising modified dnasex gene
ATE375398T1 (de) Testverfahren für lupus-anticoagulans und testreagenz
ATE321875T1 (de) Serologisches in-vitro-verfahren zur diagnose von infektiöser endokarditis
DK1414859T5 (da) Monoklonale anti-SSRP-1-antistoffer og hybridomer som producerer antistofferne

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1416965

Country of ref document: EP